EUVIMEDEUVIMED entdecken
MetaanalyseÜbersichtsarbeitOpen Access · CC BY 4.0

Safety and Efficacy of Inclisiran in Hyperlipidemia: An Updated Meta‐Analysis of Randomised Controlled Trials

Jawad Basit, Mushood Ahmed iD, Priyansha Singh iD, Areeba Ahsan, Eeshal Zulfiqar, Javed Iqbal iD, Maurish Fatima, Prakash Upreti, Mohammad Hamza iD, M Chadi Alraies

Endocrinology, Diabetes & Metabolism · 2025-03 · 8 (2)

DOI: 10.1002/edm2.70039 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Endocrinology, Diabetes & Metabolism, online erschienen am 14.03.2025. Verfasst von Jawad Basit und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan. Hauptthemen laut MEDLINE: Hyperlipidemias, RNA, Small Interfering. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Inclisiran, a small interfering RNA (siRNA), reduces the levels of low‐density lipoproteins (LDL) in the body by preventing the hepatic synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9). However, there is limited pooled data regarding the efficacy and safety of inclisiran in patients with hypercholesterolemia.

Methods

PubMed/MEDLINE, Embase and the Cochrane Library were searched by investigators from inception till July 2024 to identify randomised controlled trials (RCTs) that investigated inclisiran in patients with hypercholesterolemia. Weighted mean differences (MDs) for continuous outcomes and risk ratios (RRs) for the dichotomous outcomes were pooled. The analysis was conducted using the random effects model, and a p ‐value of < 0.05 was considered statistically significant.

Results

A total of 8 RCTs reporting data for 5016 patients were included in the pooled analysis. Our pooled analysis demonstrated that inclisiran was associated with a significant decline in the % of LDL‐C levels (MD = −50.42, 95% CI: −56.15 to −44.70), % of PCSK9 levels (MD = −78.57, 95% CI: −81.64 to −75.50), % of total cholesterol levels in the body (MD = −31.22, 95% CI: −33.08.15 to −29.37), and apo B levels (MD = −41.47, 95% CI: −44.83 to −38.11) when compared with the control group. The risk of all‐cause death, cardiovascular death, major adverse cardiovascular events, myocardial infarction, stroke, and serious adverse events remained comparable ( p > 0.05) across the two groups.

Conclusion

Inclisiran reduces LDL‐C, PCSK9, cholesterol and apo‐B levels in the body without increasing the risk of serious adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperlipidemiasRNA, Small InterferingHumansRandomized Controlled Trials as TopicCholesterol, LDLProprotein Convertase 9Treatment Outcome

Stichwörter der Autor:innen

Inclisiranhyperlipidemiameta‐analysis

Substanzen

ALN-PCSCholesterol, LDLPCSK9 protein, humanProprotein Convertase 9RNA, Small Interfering

Autor:innen und Institutionen

  • Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
  • Smt. Nathiba Hargovandas Lakhmichand Municipal Medical College, Ahmedabad, India.
  • Department of Medicine, Foundation University Medical College, Islamabad, Pakistan.
  • Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
  • Nursing Department Hamad Medical Corporation Doha, Doha, Qatar.
  • Department of Medicine, King Edward Medical University, Lahore, Pakistan.

ORCID-Profile: Mushood Ahmed, Priyansha Singh, Javed Iqbal, Mohammad Hamza

Zitieren

APA

Basit, J., Ahmed, M., Singh, P., Ahsan, A., Zulfiqar, E., Iqbal, J., Fatima, M., Upreti, P., Hamza, M., & Alraies, M. C. (2025). Safety and Efficacy of Inclisiran in Hyperlipidemia: An Updated Meta‐Analysis of Randomised Controlled Trials. Endocrinology, Diabetes & Metabolism, 8(2). https://doi.org/10.1002/edm2.70039

Vancouver

Basit J, Ahmed M, Singh P, Ahsan A, Zulfiqar E, Iqbal J, et al. Safety and Efficacy of Inclisiran in Hyperlipidemia: An Updated Meta‐Analysis of Randomised Controlled Trials. Endocrinology, Diabetes & Metabolism. 2025;8(2). doi:10.1002/edm2.70039

BibTeX
@article{Basit2025,
  author = {Basit, Jawad and Ahmed, Mushood and Singh, Priyansha and Ahsan, Areeba and Zulfiqar, Eeshal and Iqbal, Javed and Fatima, Maurish and Upreti, Prakash and Hamza, Mohammad and Alraies, M Chadi},
  title = {Safety and Efficacy of Inclisiran in Hyperlipidemia: An Updated Meta‐Analysis of Randomised Controlled Trials},
  journal = {Endocrinology, Diabetes & Metabolism},
  year = {2025},
  volume = {8},
  number = {2},
  doi = {10.1002/edm2.70039}
}
Kostenlos starten →